Most Read Articles
01 Dec 2017
At a symposium during the 25th Congress of the Obstetrical and Gynaecological Society of Malaysia in Kuala Lumpur, Professor Susan Davis discussed the unique implications of women living decades beyond menopause, and how healthcare professionals can best manage menopausal symptoms in the short and long term.
Dr Joslyn Ngu, 04 Dec 2017

Making genetic testing mainstream, allows more patients to be tested, identifies more carriers and enables appropriate stratification of treatment and outcomes, says an expert.

28 Nov 2016
The median duration of progression-free survival (PFS) can be significantly prolonged among patients with platinum-sensitive recurrent ovarian cancer who receive the poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhibitor niraparib as maintenance therapy, according to a recent phase III trial.
Menelik MH Lee, MBBS, MRCOG, FHKCOG, FHKAM; Charles J Carter, MBChB, FRCS(urol); Tyrone T Carpenter, MBBS, BSc, MRCOG, MD, 01 Jun 2014

Laparoscopic partial cystectomy is established as the optimal treatment of full thickness bladder endometriosis. Complete excision of the lesion is essential however over excision risks unnecessary reduction in bladder volume and may risk ureteric obstruction. The following case demonstrates a new technique of cystoscopic mapping and laparoscopic resection of bladder endometriosis, allowing complete removal of the endometriotic nodule while sparing maximum bladder capacity and minimising risk of injury to the ureteric orifices.

Transdermal oestradiol halves incidence of menopause-related depression

27 Nov 2017
Transdermal oestradiol added to progesterone reduces menopause-related depression, researchers reported at the annual meeting of The North American Menopause Society in Philadelphia, US.

Depressive symptoms were reduced in women assigned to the active treatment vs those on placebo (17.3 percent vs 32.3 percent; p<0.05) one year after treatment with 0.1 mg of oestradiol and 200 mg micronized intramuscular progesterone. Women who were not on hormonal treatment were also more likely to report a score of 16 or greater on the Center for Epidemiologic Studies-Depression (CES-D) scale, which indicates depression, at least once during treatment vs women on oestradiol (odds ratio [OR], 5.3; p<0.01). Those on oestradiol and progesterone treatment who reported high amounts of stressful life events prior to the study had a lower CES-D score vs those on placebo.

The study involved 172 healthy perimenopausal or early postmenopausal women without a diagnosis of major depressive disorders, bipolar, or any other psychotic disorder at enrolment. The women were randomized in a 1:1 ratio to active treatment vs placebo. All women (age, 45–60 years) were not on any background medications.

Transdermal oestradiol was administered at 0.025 mg for 2 weeks, and increased to 0.05 mg for 4 weeks. A dose of 0.1 mg was maintained throughout the study with micronized progesterone 200 mg, administered for 12 days, every 2–3 months. Patients on the control group received placebo.

The benefits of combined oestradiol and progesterone therapy were noted in early perimenopausal women but not in postmenopausal women. History of depression, physical or sexual abuse, and baseline vasomotor symptoms and oestradiol levels did not change the treatment effects.

The researchers said they used 0.1 mg of oestradiol in the study as the dose has been showed to decrease ovulation during menopause transition.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Dec 2017
At a symposium during the 25th Congress of the Obstetrical and Gynaecological Society of Malaysia in Kuala Lumpur, Professor Susan Davis discussed the unique implications of women living decades beyond menopause, and how healthcare professionals can best manage menopausal symptoms in the short and long term.
Dr Joslyn Ngu, 04 Dec 2017

Making genetic testing mainstream, allows more patients to be tested, identifies more carriers and enables appropriate stratification of treatment and outcomes, says an expert.

28 Nov 2016
The median duration of progression-free survival (PFS) can be significantly prolonged among patients with platinum-sensitive recurrent ovarian cancer who receive the poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhibitor niraparib as maintenance therapy, according to a recent phase III trial.
Menelik MH Lee, MBBS, MRCOG, FHKCOG, FHKAM; Charles J Carter, MBChB, FRCS(urol); Tyrone T Carpenter, MBBS, BSc, MRCOG, MD, 01 Jun 2014

Laparoscopic partial cystectomy is established as the optimal treatment of full thickness bladder endometriosis. Complete excision of the lesion is essential however over excision risks unnecessary reduction in bladder volume and may risk ureteric obstruction. The following case demonstrates a new technique of cystoscopic mapping and laparoscopic resection of bladder endometriosis, allowing complete removal of the endometriotic nodule while sparing maximum bladder capacity and minimising risk of injury to the ureteric orifices.